Identifying relapse mechanisms in ETV6-RUNX1 ALL patients
Research type
Research Study
Full title
Use of high throughput sequencing to identity mechanisms of relapse in ETV6-RUNX1 paediatric acute lymphoblastic leukaemia
IRAS ID
199828
Contact name
Sujith Samarasinghe
Contact email
Sponsor organisation
Great Ormond Street Hospital NHS Foundation Trust
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
Acute lymphoblastic leukaemia (ALL) is the most common type of cancer in children. Although the treatment for ALL has improved, it is an aggressive disease and many children still relapse. The outcome from relapse is very poor and it is essential to learn more about the changes that occur at relapse. Therefore, we plan to use high throughput sequencing (HTS) to identify all genetic mutations that occur in the leukaemic cells at relapse. We will perform this in the most common subgroup of ALL, called ETV6-RUNX1 ALL. We hope that the identification of new mutations will provide important information on the prevention and treatment of relapse in childhood ALL.
REC name
South Central - Hampshire A Research Ethics Committee
REC reference
16/SC/0054
Date of REC Opinion
26 Jan 2016
REC opinion
Favourable Opinion